DeLLphi-300: Updated Data From Phase I Study of Tarlatamab, a DLL3-Targeted T-Cell Engager, in Relapsed/Refractory SCLC

August 6-9, 2022; Vienna, Austria
Tarlatamab showed promising antitumor activity with durable responses and an acceptable safety profile for patients with relapsed/refractory SCLC after multiple lines of therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 200 KB
Released: August 12, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.
Turning Point Therapeutics, Inc.

Related Content

Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Released: January 23, 2023

On-demand webcast from a live satellite symposium at SITC 2022 on current use of IO therapy in lung cancer, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 17, 2023 Expired: January 16, 2024

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings